Analysts expect that Fate Therapeutics Inc (NASDAQ:FATE) will report earnings of ($0.32) per share for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Fate Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.39) and the highest estimate coming in at ($0.18). Fate Therapeutics posted earnings per share of ($0.37) in the same quarter last year, which suggests a positive year over year growth rate of 13.5%. The firm is scheduled to report its next earnings results on Monday, August 5th.

On average, analysts expect that Fate Therapeutics will report full year earnings of ($1.30) per share for the current year, with EPS estimates ranging from ($1.47) to ($0.86). For the next fiscal year, analysts expect that the firm will post earnings of ($1.30) per share, with EPS estimates ranging from ($1.68) to ($0.47). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that cover Fate Therapeutics.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07). Fate Therapeutics had a negative return on equity of 54.30% and a negative net margin of 1,138.12%. The firm had revenue of $2.63 million during the quarter, compared to analysts’ expectations of $2.01 million. During the same quarter in the prior year, the firm earned ($0.27) EPS. The firm’s revenue was up 156.3% compared to the same quarter last year.

A number of brokerages recently issued reports on FATE. Citigroup set a $27.00 price target on shares of PhaseBio Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, May 24th. Leerink Swann began coverage on shares of Affimed in a research note on Thursday, March 28th. They issued an “outperform” rating and a $4.17 price target for the company. BidaskClub downgraded shares of Waterstone Financial from a “hold” rating to a “sell” rating in a research note on Friday, June 21st. Svb Leerink began coverage on shares of Fate Therapeutics in a research note on Thursday, March 28th. They issued an “outperform” rating and a $20.00 price target for the company. Finally, Roth Capital decreased their price target on shares of Diamondback Energy from $166.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, June 7th. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Fate Therapeutics presently has an average rating of “Buy” and an average price target of $23.43.

In other news, insider Daniel D. Shoemaker sold 12,500 shares of the business’s stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $20.21, for a total transaction of $252,625.00. Following the completion of the sale, the insider now owns 148,091 shares in the company, valued at approximately $2,992,919.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider J Scott Wolchko sold 14,335 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $19.37, for a total transaction of $277,668.95. Following the sale, the insider now owns 389,216 shares of the company’s stock, valued at approximately $7,539,113.92. The disclosure for this sale can be found here. Insiders have sold a total of 119,410 shares of company stock valued at $2,614,655 in the last 90 days. Insiders own 23.19% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its position in Fate Therapeutics by 45.0% in the 4th quarter. BlackRock Inc. now owns 5,031,783 shares of the biopharmaceutical company’s stock valued at $64,557,000 after purchasing an additional 1,562,252 shares during the last quarter. Victory Capital Management Inc. increased its stake in Fate Therapeutics by 49.7% in the 1st quarter. Victory Capital Management Inc. now owns 1,974,174 shares of the biopharmaceutical company’s stock valued at $34,686,000 after buying an additional 655,314 shares during the period. Northern Trust Corp increased its stake in Fate Therapeutics by 17.8% in the 4th quarter. Northern Trust Corp now owns 735,512 shares of the biopharmaceutical company’s stock valued at $9,437,000 after buying an additional 110,936 shares during the period. Geode Capital Management LLC increased its stake in Fate Therapeutics by 36.3% in the 4th quarter. Geode Capital Management LLC now owns 702,179 shares of the biopharmaceutical company’s stock valued at $9,008,000 after buying an additional 186,927 shares during the period. Finally, Millennium Management LLC increased its stake in Fate Therapeutics by 269.0% in the 4th quarter. Millennium Management LLC now owns 587,640 shares of the biopharmaceutical company’s stock valued at $7,539,000 after buying an additional 428,399 shares during the period. Hedge funds and other institutional investors own 93.28% of the company’s stock.

Fate Therapeutics stock traded up $1.11 during trading on Monday, reaching $22.48. The stock had a trading volume of 667,990 shares, compared to its average volume of 718,300. Fate Therapeutics has a 52-week low of $8.64 and a 52-week high of $22.82. The firm has a 50 day moving average of $19.85. The company has a debt-to-equity ratio of 0.26, a quick ratio of 6.40 and a current ratio of 6.40. The stock has a market capitalization of $1.39 billion, a PE ratio of -18.89 and a beta of 1.65.

About Fate Therapeutics

Fate Therapeutics, Inc operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.

Featured Story: Exchange-Traded Funds (ETFs)

Get a free copy of the Zacks research report on Fate Therapeutics (FATE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.